A case of long-term sildenafil therapy in a young dog with pulmonary hypertension.
A 7-month-old male Papillon was presented to us with mild dyspnea, cyanosis and a diastolic murmur detected by cardiac auscultation. Echocardiography revealed severe pulmonary arterial hypertension (PH), and administration of 1 mg/kg of oral sildenafil, a phosphodiesterase type 5 (PDE5) inhibitor, twice daily was initiated. Exercise capacity, cyanosis, dyspnea and cardiac murmur were improved after therapy for 4 weeks. PCV was remarkably high (74%) after therapy for 3 years, however, increasing the dose of sildenafil decreased this value (60%). Follow-up after therapy for 4 years revealed that treatment with oral sildenafil only continued to provide the dog with an excellent quality of life, without any side effects.
Toyoshima
Yumiko
Y
Toyoshima Animal Hospital, Aichi, Japan. pomerin@mpd.biglobe.ne.jp
Kanemoto
Isamu
I
Arai
Satoshi
S
Toyoshima
Hiroaki
H
D000818:Animals; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D006976:Hypertension, Pulmonary / Q000188:drug therapy / Q000662:veterinary*; D008297:Male; D010879:Piperazines / Q000627:therapeutic use*; D011687:Purines / Q000627:therapeutic use; D000068677:Sildenafil Citrate; D013450:Sulfones / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000627:therapeutic use*
D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014665:Vasodilator Agents; D000068677:Sildenafil Citrate